Menu
Not yet recruiting NCT07140640

Effect of a 20% Reduction in Hyperbaric Bupivacaine Dose on High Spinal Block Incidence in Cesarean Delivery: A Risk-Stratified Randomized Controlled Trial.

Phase IV Interventional Cesarean Section Complications

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Hyperbaric Bupivacaine HCl 0.5% 12.5 mg, Hyperbaric Bupivacaine HCl 0.5% 10 mg.
Who it may be relevant to
Registry conditions: Cesarean Section Complications. Basic parameters: 18 years — 45 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Effect of a 20% Reduction in Hyperbaric Bupivacaine Dose on High Spinal Block Incidence in Cesarean Delivery: A Risk-Stratified Randomized Controlled Trial.

Detailed description

This an interventional study comparing effect of Standard dose of Hyperbaric bupivacaine with 20% reduction of dose of Hyperbaric Bupivacaine in Elective Cesarean Delivery.

First, we determaine if the patient ( low - moderate - high ) risk to High spinal complication or not according to : Age-weight-BMI-Height.

Then , Randomly we gave the patients " Full dose of Hyperbaric Bupivacaine OR 20% reduction of hyperbric Bupivacaine " in spinal anaethsia .

Post anesthesia evaluation:

to assess incomplete sensory and/or motor blockade after spinal anesthesia for cesarean section is the Bromage Scale for motor blockade and a sensory block assessment using pinprick or cold sensation.

1. Bromage Scale for Motor Blockade:

This scale assesses the degree of motor block in the lower limbs: * Grade 0: No paralysis, full flexion of knees and feet. * Grade 1: Inability to raise extended legs; can move knees and feet. * Grade 2: Inability to flex knees; can move feet. * Grade 3: Complete paralysis of the lower limbs.

Incomplete motor blockade would typically be Bromage 1 or 2. 2. Sensory Block Assessment:

* Sensory block is often assessed using a pinprick test or cold sensation (ice or alcohol swab). * Levels are recorded using dermatome levels (T10, T6, T4, etc.). * Incomplete sensory block means failure to achieve adequate sensory block (T4-T6 for cesarean section), requiring additional analgesia or conversion to general anesthesia.

Interventions

  • Drug Hyperbaric Bupivacaine HCl 0.5% 12.5 mg
    1- Standard dose group: receiving the typical dose of hyperbaric bupivacaine (12.5 mg hyperbaric bupivacaine + 25 mcg fentanyl).
  • Drug Hyperbaric Bupivacaine HCl 0.5% 10 mg
    2- Reduced dose group: receiving a20% reduced dose of hyperbaric bupivacaine (10 mg hyperbaric bupivacaine + 25 mcg fentanyl).

Primary outcome measures

  • 1-Reduced Incidence of HSB [Time frame: operation time]
  • 1-Reduced Incidence of HSB [Time frame: first 20 minutes]

Eligibility criteria

Inclusion criteria

  • • Pregnant women aged 18-45 years.
  • ASA physical status II-III.

Exclusion criteria

  • • Twin pregnancies.
  • Contraindications to spinal anesthesia (e.g., coagulopathy, infection).
  • Patients with incomplete preoperative data for risk stratification.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Factorial
Masking
Open label
Primary purpose
Prevention

Study locations

Egypt · 1 center
  • Aswan university — Aswān

Publications

  • Benjhawaleemas P, Sakolnagara BBN, Tanasansuttiporn J, Chatmongkolchart S, Oofuvong M. Risk prediction score for high spinal block in patients undergoing cesarean delivery: a retrospective cohort study. BMC Anesthesiol. 2024 Nov 11;24(1):406. doi: 10.1186/s12871-024-02799-w. PMID 39528929

Identifiers

NCT: NCT07140640 · 1084-3-25

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗